Patents by Inventor Michael E. Houston

Michael E. Houston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11684584
    Abstract: Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: June 27, 2023
    Assignee: Genevant Sciences GmbH
    Inventors: Debashish Roy, Jean-Rene E. Ella-Menye, Sean D. Monahan, Pierrot Harvie, Anna Galperin, Michael E. Houston, Mary G. Prieve
  • Publication number: 20190388551
    Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 26, 2019
    Applicant: GENEVANT SCIENCES GMBH
    Inventors: Sean D. MONAHAN, Michael S. DeCLUE, Pierrot HARVIE, Russell N. JOHNSON, Amber E. PASCHAL, Mary G. PRIEVE, Debashish ROY, Charbel DIAB, Michael E. HOUSTON, Anna GALPERIN, Maher QABAR
  • Publication number: 20100240731
    Abstract: Lipopeptide compounds comprising a peptide having 2 to 100 amino acid residues, and having a lipophilic group attached to at least one terminus of the peptide or to at least one amino acid residue of the peptide, and salts and uses thereof. The lipophilic group may be attached to the N-terminus, C-terminus or both termini of the peptide. The lipophilic group may be attached to at least one interal amino acid residue (i.e., an amino acid residue that is not the N-terminus or the C-terminus amino acid residue of the peptide). The lipophilic group may be attached to either termini or both and at least one internal amino acid residue.
    Type: Application
    Filed: March 30, 2010
    Publication date: September 23, 2010
    Applicant: MDRNA, INC.
    Inventors: Roger C. Adami, Michael E. Houston, Rachel E. Johns
  • Publication number: 20090220435
    Abstract: Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and delivery. Permeability can be enhanced with reversibility. Compounds and components for enhanced delivery may be peptide or protein variants, conjugates, or other analog types and structures.
    Type: Application
    Filed: July 27, 2006
    Publication date: September 3, 2009
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Shu-Chih Chen Quay, Kunyuan Cui, Anthony P. Sileno, Paul Hickok Johnson, Michael E. Houston, Henry R. Costantino, Michael V. Templin
  • Publication number: 20080261304
    Abstract: A double-stranded RNA, preferably a small, interfering (si)RNA or a siHybrid, to which cholesterol moieties are linked.
    Type: Application
    Filed: January 11, 2008
    Publication date: October 23, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Mohammad Ahmadian, Kunyuan Cui, Lishan Chen, Shu-Chih Chen, Michael E. Houston
  • Publication number: 20080076701
    Abstract: Dicer substrate RNA peptide conjugates comprising a double stranded ribonucleic acid (dsRNA) having a sense strand and an antisense strand, and a peptide, wherein the dicer substrate RNA is conjugated to the peptide, and compositions and methods of use thereof.
    Type: Application
    Filed: August 10, 2007
    Publication date: March 27, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Paul Hickok Johnson, Michael E. Houston, Roger C. Adami, Renata Fam
  • Publication number: 20070275923
    Abstract: What is described is a composition for delivery of a RNA molecule to a cell, comprising: a double stranded RNA (dsRNA) molecule of about 15 to about 40 base pairs; and a polynucleotide delivery-enhancing peptide, comprising a region of alternating lysine and histidine residues, or of alternating D and L forms of arginine.
    Type: Application
    Filed: February 16, 2007
    Publication date: November 29, 2007
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Lishan Chen, Michael E. Houston, Roger C. Adami, James Anthony McSwiggen, Sasha J. Mayer, Steven C. Quay
  • Publication number: 20040254146
    Abstract: Disclosed are novel carboxylate salts of galantamine including galantamine gluconate, galantamine lactate, galantamine citrate and galantamine glucarate. These salts of galantamine have more than a 5 fold increase in solubility compared to galantamine hydrobromide. These galantamine salts can be administered to an individual to inhibit acetylcholinesterase in the treatment of such diseases as Alzheimer's disease, atony of the smooth muscle of the intestinal tract and urinary bladder, glaucoma, myasthenia gravis, and termination of the effects of competitive neuromuscular blocking drugs.
    Type: Application
    Filed: April 23, 2004
    Publication date: December 16, 2004
    Applicant: Nastech Pharmaceutical Company Inc.
    Inventors: Steven C. Quay, Henry R. Costantino, Michael E. Houston, Alexis Kays Leonard
  • Publication number: 20030021795
    Abstract: This invention relates to the use of a coiled-coil structural scaffold to generate structure-specific peptides, including synthetic peptides derived from naturally occurring proteins of various origin. The structure of the synthetic peptides utilizes a scaffold of heptad repeat units into which epitopes from coiled-coil regions of native proteins are spliced. In particular, the synthetic peptides may be based on microbial proteins, especially surface proteins, which occur naturally in the coiled-coil form such as pneumococcal surface proteins A and C. The synthetic peptides are immunogenic and can be used to elicit an immune response in an animal. Accordingly, they are useful as vaccines or to stimulate antibody production or cell-mediated immunity to the naturally occurring protein.
    Type: Application
    Filed: June 14, 2001
    Publication date: January 30, 2003
    Inventors: Michael E. Houston, Robert Hodges